Pharmacological Control of Rate and Maintenance of Sinus Rhythm

Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709–715. Tomita M, Spinale FG, Crawford FA, et al. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circulation 1991;83:635–644. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986;57:563–570. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992;326:1264–1271. Repique LJ, Shah SN, Marais GE. Atrial fibrillation 1992: Management strategies in flux. Chest 1992;101:1095–1103. Digitalis in Acute Atrial Fibrillation Trial Group. Intravenous digoxin in acute atrial fibrillation. Eur Heart J 1997;18:649–654. Jordaens L, Trouerbach J, Calle P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 1997;18:643–648. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J 1985;290:9–11. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86–90. Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: Randomized crossover study. Int J Cardiol 1995;52:167–174. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multicenter study. J Am Coll Cardiol 1991; 18:891–897. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and trial flutter. Am J Cardiol 1989;63:1046-1051. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884–889. Heywood JT, Graham B, Marais GE, et al. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 1991;67:1150–1152. Dibianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984;108:1121. Esmalol vs. Placebo Multicenter Study Group. Comparison of the efficacy and safety of esmolol, a short-acting betablocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986;111:42. Shettigar UR, Toole JG, Appunn DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. Am Heart J 1993;126:368–374. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. Circulation 1995;92: 1954–1968. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281–284. Allessie MA, Banke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. Circ Res 1977;41:9–18. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990;82:1106–1116. Disch DL, Greenberg ML, Holzberger PT, et al. Managing chronic atrial fibrillation: A Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994;120:449–457. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine associated long Q-T syndrome: Implications for patient care. Am Heart J 1986;111:1088–1093. Selzer A, Wray W. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17–26. Falk RH. Proarrhythmic response to atrial antiarrhythmic therapy. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanism and Management. New York: Raven Press, 1992:283–306 Cowan JC. Antiarrhythmic drugs in the management of atrial fibrillation. Br Heart J 1993;70:304–306. Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527–532. Kosowshy BI, Taylor J, Lown B, et al. Long term use of procainamide following acute myocardial infarction. Circulation 1973;47:1204–1210. Podrid P, Schoeneberger A, Lown B, et al. Congestive heart failure caused by oral disopyramide. N Engl J Med 1980; 302:614–617. Tzivoni D, Keren A, Stem S, et al. Disopyramide-induced torsades de pointes. Arch Intern Med 1981;141:946–947. Opie HL. Drugs of the Heart. Philadelphia: WB Saunders, 1991. Chimienti M, Cullen MT, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996;77:60A–65A. Aliot E, Denjoy I, et al. Comparison of the safety and efficacy of flecainide versus propafeneone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:66A–71A. Hopson JR, Buxton AE, Rinkenberger RL, et al. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a multicenter trial. Am J Cardiol 1996;77:72A–82A. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1996;20:527–532. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemtic hypertension. AmJCardiol 1992; 70:69–72. Suttorp MJ, Kingma H, Jessurun ER, et al. The value of class IC antiarhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722–1772. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550–2557. Weiner P, Ganam R, Ganem R, et al. Clinical course of recent-onset atrial fibrillation treated with oral propafenone. Chest 1994;105:1013–1016. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932–1939. Hohnloser SH, VandeLoo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparsion of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852–858. Mitchell LB, Wyse DG, Duff HJ. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987;4:810–818. Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J. Cardiol 1995;76:47–50. Gosselink AM, Crijns HJ, VanGelder IC, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267: 3289–3293. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous Ibultilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996;28:130–136. Stambler BS, Wood MA, Ellennbogen KA, Perry KT, Wakefield LK, Vanderlugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613–1621. Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997;29:385–90. Sahar DI, Reiffel JA, Bigger JT, et al. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. Am Heart J 1989;117:562. Waldo AL, Camm AJ, DeRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7–12.